Family-Wide Comparative Analysis of Cytidine and Methylcytidine Deamination by Eleven Human APOBEC Proteins

Journal of Molecular Biology

Volumn 429, Issue 12, 2017, Pages 1787-1799

  Ito, Fumiaki ^a   Fu, Yang ^a   Kao, Shen Chi A ^a   Yang, Hanjing ^a   Chen, Xiaojiang S ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

APOBEC proteins; C and mC deamination; cytidine deaminase; mC selectivity factor

Indexed keywords

APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE 1; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE 2; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE 3A; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE 3B; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE 3C; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE 3D; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE 3F; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE 3G; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE 3H; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE 4; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE AID; CYTIDINE; DEAMINASE; DNA; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; CYTOSINE;

ARTICLE; DEAMINATION; DNA BINDING; ENZYME ACTIVITY; ENZYME SPECIFICITY; HUMAN; MUTATIONAL ANALYSIS; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; ANALOGS AND DERIVATIVES; DNA MUTATIONAL ANALYSIS; GENETICS; ISOLATION AND PURIFICATION; METABOLISM;

APOBEC DEAMINASES; CYTOSINE; DEAMINATION; DNA MUTATIONAL ANALYSIS; HUMANS; SUBSTRATE SPECIFICITY;

EID: 85019359917     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2017.04.021     Document Type: Article

References (75)

1. Conticello, S.G., The AID/APOBEC family of nucleic acid mutators. Genome Biol., 9, 2008, 229.
2. Macduff, D.A., Harris, R.S., Directed DNA deamination by AID/APOBEC3 in immunity. Curr. Biol. 16 (2006), R186–R189.
3. Prochnow, C., Bransteitter, R., Klein, M.G., Goodman, M.F., Chen, X.S., The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature 445 (2007), 447–451.
4. Holden, L.G., Prochnow, C., Chang, Y.P., Bransteitter, R., Chelico, L., Sen, U., et al. Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456 (2008), 121–124.
5. Bransteitter, R., Prochnow, C., Chen, X.S., The current structural and functional understanding of APOBEC deaminases. Cell. Mol. Life Sci. 66 (2009), 3137–3147.
6. Chen, K.M., Harjes, E., Gross, P.J., Fahmy, A., Lu, Y., Shindo, K., et al. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452 (2008), 116–119.
7. Shandilya, S.M., Nalam, M.N., Nalivaika, E.A., Gross, P.J., Valesano, J.C., Shindo, K., et al. Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure 18 (2010), 28–38.
8. Kitamura, S., Ode, H., Nakashima, M., Imahashi, M., Naganawa, Y., Kurosawa, T., et al. The APOBEC3C crystal structure and the interface for HIV-1 Vif binding. Nat. Struct. Mol. Biol. 19 (2012), 1005–1010.
9. Byeon, I.J., Ahn, J., Mitra, M., Byeon, C.H., Hercik, K., Hritz, J., et al. NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificity. Nat. Commun., 4, 2013, 1890.
10. Bohn, M.F., Shandilya, S.M., Albin, J.S., Kouno, T., Anderson, B.D., McDougle, R.M., et al. Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain. Structure 21 (2013), 1042–1050.
11. Siu, K.K., Sultana, A., Azimi, F.C., Lee, J.E., Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F. Nat. Commun., 4, 2013, 2593.
12. Shi, K., Carpenter, M.A., Kurahashi, K., Harris, R.S., Aihara, H., Crystal structure of the DNA deaminase APOBEC3B catalytic domain. J. Biol. Chem. 290 (2015), 28,120–28,130.
13. Moris, A., Murray, S., Cardinaud, S., AID and APOBECs span the gap between innate and adaptive immunity. Front. Microbiol., 5, 2014, 534.
14. Refsland, E.W., Harris, R.S., The APOBEC3 family of retroelement restriction factors. Curr. Top. Microbiol. Immunol. 371 (2013), 1–27.
15. Desimmie, B.A., Delviks-Frankenberrry, K.A., Burdick, R.C., Qi, D., Izumi, T., Pathak, V.K., Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J. Mol. Biol. 426 (2014), 1220–1245.
16. Malim, M.H., Bieniasz, P.D., HIV restriction factors and mechanisms of evasion. Cold Spring Harb. Perspect. Med., 2, 2012, a006940.
17. Tan, L., Sarkis, P.T., Wang, T., Tian, C., Yu, X.F., Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB J. 23 (2009), 279–287.
18. OhAinle, M., Kerns, J.A., Li, M.M., Malik, H.S., Emerman, M., Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 4 (2008), 249–259.
19. Harris, R.S., Liddament, M.T., Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 4 (2004), 868–877.
20. Prochnow, C., Bransteitter, R., Chen, X.S., APOBEC deaminases-mutases with defensive roles for immunity. Sci. China C Life Sci. 52 (2009), 893–902.
21. Prochnow, C., Goodman, M.F., Chen, X.S., The prospct of APOBEC3G for the future of HIV therapy. HIV Ther. 3 (2009), 7–10.
22. Bransteitter, R., Pham, P., Calabrese, P., Goodman, M.F., Biochemical analysis of hyper-mutational targeting by wild type and mutant AID. J. Biol. Chem. 279 (2004), 51,612–51,621.
23. Honjo, T., Muramatsu, M., Fagarasan, S., AID: how does it aid antibody diversity?. Immunity 20 (2004), 659–668.
24. Ta, V.T., Nagaoka, H., Catalan, N., Durandy, A., Fischer, A., Imai, K., et al. AID mutant analyses indicate requirement for class-switch-specific cofactors. Nat. Immunol. 4 (2003), 843–848 (Epub 2003 Aug 10).
25. Chaudhuri, J., Tian, M., Khuong, C., Chua, K., Pinaud, E., Alt, F.W., Transcription-targeted DNA deamination by the AID antibody diversification enzyme. Nature 422 (2003), 726–730.
26. Shinkura, R., Ito, S., Begum, N.A., Nagaoka, H., Muramatsu, M., Kinoshita, K., et al. Separate domains of AID are required for somatic hypermutation and class-switch recombination. Nat. Immunol. 5 (2004), 707–712 (Epub 2004 Jun 13).
27. Revy, P., Muto, T., Levy, Y., Geissmann, F., Plebani, A., Sanal, O., et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2). Cell 102 (2000), 565–575.
28. Navaratnam, N., Morrison, J.R., Bhattacharya, S., Patel, D., Funahashi, T., Giannoni, F., et al. The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase. J. Biol. Chem. 268 (1993), 20,709–20,712.
29. Li, J., Chen, Y., Li, M., Carpenter, M.A., McDougle, R.M., Luengas, E.M., et al. APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells. J. Mol. Biol. 426 (2014), 1296–1307.
30. Li, D., Liu, J., Kang, F., Guan, W., Gao, X., Wang, Y., et al. Core-APOBEC3C chimerical protein inhibits hepatitis B virus replication. J. Biochem. 150 (2011), 371–374.
31. Krisko, J.F., Martinez-Torres, F., Foster, J.L., Garcia, J.V., HIV restriction by APOBEC3 in humanized mice. PLoS Pathog., 9, 2013, e1003242.
32. Vartanian, J.P., Guetard, D., Henry, M., Wain-Hobson, S., Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 320 (2008), 230–233.
33. Wang, Z., Wakae, K., Kitamura, K., Aoyama, S., Liu, G., Koura, M., et al. APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon beta interferon stimulation. J. Virol. 88 (2014), 1308–1317.
34. Warren, C.J., Xu, T., Guo, K., Griffin, L.M., Westrich, J.A., Lee, D., et al. APOBEC3A functions as a restriction factor of human papillomavirus. J. Virol. 89 (2015), 688–702.
35. Suspene, R., Guetard, D., Henry, M., Sommer, P., Wain-Hobson, S., Vartanian, J.P., Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 8321–8326.
36. Baumert, T.F., Rosler, C., Malim, M.H., von Weizsacker, F., Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C. Hepatology 46 (2007), 682–689.
37. Gonzalez, M.C., Suspene, R., Henry, M., Guetard, D., Wain-Hobson, S., Vartanian, J.P., Human APOBEC1 cytidine deaminase edits HBV DNA. Retrovirology, 6, 2009, 96.
38. Lei, Y.C., Hao, Y.H., Zhang, Z.M., Tian, Y.J., Wang, B.J., Yang, Y., et al. Inhibition of hepatitis B virus replication by APOBEC3G in vitro and in vivo. World J. Gastroenterol. 12 (2006), 4492–4497.
39. Xiao, X., Li, S.X., Yang, H., Chen, X.S., Crystal structures of APOBEC3G N-domain alone and its complex with DNA. Nat. Commun., 7, 2016, 12,193.
40. Lada, A.G., Krick, C.F., Kozmin, S.G., Mayorov, V.I., Karpova, T.S., Rogozin, I.B., et al. Mutator effects and mutation signatures of editing deaminases produced in bacteria and yeast. Biochemistry (Mosc) 76 (2011), 131–146.
41. Harris, R.S., Petersen-Mahrt, S.K., Neuberger, M.S., RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell 10 (2002), 1247–1253.
42. Bransteitter, R., Pham, P., Scharff, M.D., Goodman, M.F., Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 4102–4107.
43. Morgan, H.D., Dean, W., Coker, H.A., Reik, W., Petersen-Mahrt, S.K., Activation-induced cytidine deaminase deaminates 5-methylcytosine in DNA and is expressed in pluripotent tissues: implications for epigenetic reprogramming. J. Biol. Chem. 279 (2004), 52,353–52,360 (Epub 2004 Sep 24).
44. Larijani, M., Frieder, D., Sonbuchner, T.M., Bransteitter, R., Goodman, M.F., Bouhassira, E.E., et al. Methylation protects cytidines from AID-mediated deamination. Mol. Immunol. 42 (2005), 599–604.
45. Nabel, C.S., Jia, H., Ye, Y., Shen, L., Goldschmidt, H.L., Stivers, J.T., et al. AID/APOBEC deaminases disfavor modified cytosines implicated in DNA demethylation. Nat. Chem. Biol. 8 (2012), 751–758.
46. Wijesinghe, P., Bhagwat, A.S., Efficient deamination of 5-methylcytosines in DNA by human APOBEC3A, but not by AID or APOBEC3G. Nucleic Acids Res. 40 (2012), 9206–9217.
47. Carpenter, M.A., Li, M., Rathore, A., Lackey, L., Law, E.K., Land, A.M., et al. Methylcytosine and normal cytosine deamination by the foreign DNA restriction enzyme APOBEC3A. J. Biol. Chem. 287 (2012), 34,801–34,808.
48. Suspene, R., Aynaud, M.M., Vartanian, J.P., Wain-Hobson, S., Efficient deamination of 5-methylcytidine and 5-substituted cytidine residues in DNA by human APOBEC3A cytidine deaminase. PLoS One, 8, 2013, e63461.
49. Fu, Y., Ito, F., Zhang, G., Fernandez, B., Yang, H., Chen, X.S., DNA cytosine and methylcytosine deamination by APOBEC3B: enhancing methylcytosine deamination by engineering APOBEC3B. Biochem. J. 471 (2015), 25–35.
50. Gu, J., Chen, Q., Xiao, X., Ito, F., Wolfe, A., Chen, X.S., Biochemical characterization of APOBEC3H variants: implications for their HIV-1 restriction activity and mC modification. J. Mol. Biol. 428 (2016), 4626–4638.
51. Caval, V., Suspene, R., Shapira, M., Vartanian, J.P., Wain-Hobson, S., A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3′UTR enhances chromosomal DNA damage. Nat. Commun., 5, 2014, 5129.
52. Popp, C., Dean, W., Feng, S., Cokus, S.J., Andrews, S., Pellegrini, M., et al. Genome-wide erasure of DNA methylation in mouse primordial germ cells is affected by AID deficiency. Nature 463 (2010), 1101–1105.
53. Bhutani, N., Brady, J.J., Damian, M., Sacco, A., Corbel, S.Y., Blau, H.M., Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature 463 (2010), 1042–1047.
54. Fritz, E.L., Rosenberg, B.R., Lay, K., Mihailovic, A., Tuschl, T., Papavasiliou, F.N., A comprehensive analysis of the effects of the deaminase AID on the transcriptome and methylome of activated B cells. Nat. Immunol. 14 (2013), 749–755.
55. Harari, A., Ooms, M., Mulder, L.C., Simon, V., Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J. Virol. 83 (2009), 295–303.
56. Wang, X., Abudu, A., Son, S., Dang, Y., Venta, P.J., Zheng, Y.H., Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity. J. Virol. 85 (2011), 3142–3152.
57. Pham, P., Bransteitter, R., Petruska, J., Goodman, M.F., Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. Nature 424 (2003), 103–107.
58. Petersen-Mahrt, S.K., Harris, R.S., Neuberger, M.S., AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 418 (2002), 99–103.
59. Burns, M.B., Lackey, L., Carpenter, M.A., Rathore, A., Land, A.M., Leonard, B., et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494 (2013), 366–370.
60. Saraconi, G., Severi, F., Sala, C., Mattiuz, G., Conticello, S.G., The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas. Genome Biol., 15, 2014, 417.
61. Dang, Y., Wang, X., Esselman, W.J., Zheng, Y.H., Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 80 (2006), 10,522–10,533.
62. Chen, Q., Xiao, X., Wolfe, A., Chen, X.S., The in vitro biochemical characterization of an HIV-1 restriction factor APOBEC3F: importance of loop 7 on both CD1 and CD2 for DNA binding and deamination. J. Mol. Biol. 428 (2016), 2661–2670.
63. Pham, P., Landolph, A., Mendez, C., Li, N., Goodman, M.F., A biochemical analysis linking APOBEC3A to disparate HIV-1 restriction and skin cancer. J. Biol. Chem. 288 (2013), 29,294–29,304.
64. Bhutani, N., Decker, M.N., Brady, J.J., Bussat, R.T., Burns, D.M., Corbel, S.Y., et al. A critical role for AID in the initiation of reprogramming to induced pluripotent stem cells. FASEB J. 27 (2013), 1107–1113.
65. Kumar, R., DiMenna, L., Schrode, N., Liu, T.C., Franck, P., Munoz-Descalzo, S., et al. AID stabilizes stem-cell phenotype by removing epigenetic memory of pluripotency genes. Nature 500 (2013), 89–92.
66. Caval, V., Suspène, R., Vartanian, J.-p., Wain-Hobson, S., Caval, V., Suspe, R., Orthologous mammalian APOBEC3A cytidine deaminases hypermutate nuclear DNA. Mol. Biol. Evol., 2013, 1–11.
67. Stenglein, M.D., Burns, M.B., Li, M., Lengyel, J., Harris, R.S., APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat. Struct. Mol. Biol. 17 (2010), 222–229.
68. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., et al. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
69. Harris, R.S., Cancer mutation signatures, DNA damage mechanisms, and potential clinical implications. Genome Med., 5, 2013, 87.
70. Leonard, B., Hart, S.N., Burns, M.B., Carpenter, M.A., Temiz, N.A., Rathore, A., et al. APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res. 73 (2013), 7222–7231.
71. Burns, M.B., Temiz, N.A., Harris, R.S., Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 45 (2013), 977–983.
72. Kuong, K.J., Loeb, L.A., APOBEC3B mutagenesis in cancer. Nat. Genet. 45 (2013), 964–965.
73. Taylor, B.J., Nik-Zainal, S., Wu, Y.L., Stebbings, L.A., Raine, K., Campbell, P.J., et al. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. elife, 2, 2013, e00534.
74. Chelico, L., Prochnow, C., Erie, D.A., Chen, X.S., Goodman, M.F., Structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G. J. Biol. Chem. 285 (2010), 16,195–16,205.
75. Shi, K., Carpenter, M.A., Banerjee, S., Shaban, N.M., Kurahashi, K., Salamango, D.J., et al. Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B. Nat. Struct. Mol. Biol. 24 (2016), 131–139.